A well controlled comparative clinical study for the effect of difluprednate (DFBA, MYSER ointment) on pityriasis rosea (Gibert).
スポンサーリンク
概要
- 論文の詳細を見る
To investigate the clinical effect of 0.05% Difluprednate ointment (DFBA, MYSER<SUP>®</SUP>ointment), a well controlled comparative study was performed on 23 patients with pityriasis rosea (Gibert) using 0. 12% betamethasone valerate (BV) as the control drug. As a result, DFBA showed significantly superlor efficacy rate (90. 9 %) to BV (72.7%). Regarding clinical utility, DFBA (100%) was also significantly superior to BV (77. 3%). No serious side effect was observed. We conclude that DFBA is an useful agent for the treatment of pityriasis rosea (Gibert).<BR>This report also refers to blood laboratory findings before and after treatment in some patients out of the 23 patients.
- 日本皮膚科学会大阪地方会の論文
日本皮膚科学会大阪地方会 | 論文
- ツベルクリン皮内反応部に出現する浸潤細胞の電顕的観察
- セフメタゾ-ル・ナトリウムによりSystemic eczematous contact-type dermatitis medicamentosaと急性腎不全を生じた1例 (単純化学物質による皮膚障害)
- 歯科金属アレルギ-による全身の扁平苔癬の1例 (接触皮膚炎とパッチテスト-4-)
- Oakmoss Allergyを示すPigmented Cosmetic Dermatitisの1例 (単純化学物質による皮膚障害)
- 漢方薬中のCinnamic系化合物による薬疹の1例 (単純化学物質による皮膚障害) -- (職業性および薬剤性皮膚炎と薬疹)